Malaysian Health Ministry (MOH) has recently announced that they will be phasing out the Covid-19 Vaccine, Sinovac which is produced by a Chinese biopharmaceutical company named Sinovac Biotech Ltd. The government will continue to administer the vaccination until supplies run out. Malaysians will continue to have five types of vaccinations in the National Immunisation Programme (NIP). These vaccines are Sinopharm, Johnson &Johnson, Pfizer-BioNTech, AstraZeneca and Cansino.
Furthermore, the country has also managed to procure 45 million doses of Pfizer Bio-NTech which is able to cover 70% of the population. As half of the Sinovac supply has already been administered, the second half will be reserved for the second dose for those who have already taken Sinovac as their first dose.
The decision to halt the supply of Sinovac stems from efficacy against the Variants of Concern (VOC) and the Variant of Interest (VOI). Data for the Delta variant on Sinovac has not been released yet. However, before the Delta variant, Sinovac has already recorded 50% efficacy in comparison to the Pfizer BioNTech vaccine which recorded a 95% effectiveness in preventing Covid-19 infections and at least 64% effective against the Delta variant.
What do you think about this article? Comment down below! Follow @jrsharing for more updates or read more content like this.
Read More:
